Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338114 | 1.00 | CYP2A6 (0.60) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL30047288 | 0.89 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL4961407 | 0.87 | CYP2A6 (0.69) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL6968526 | 0.85 | NR1D1 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL6971248 | 0.85 | CYP2A6 (0.57) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL1539256 | 0.83 | SLC5A2 (0.50) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL6970206 | 0.81 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL7086153 | 0.81 | CYP2A6 (0.53) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL25444211 | 0.81 | ADORA2A (0.40) | CYP2A6ASIC3LOXL2ADRB2AGXT | |
| SCHEMBL12425730 | 0.80 | CYP2A6 (0.51) | CYP2A6ASIC3LOXL2ADRB2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185350-A | Weeding type bio-organic fertilizer, preparation method and application | 中科韶华(四川)牧业研究院有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-107629033-A | A kind of synthetic method of [60] fullerene benzothiophene derivative that DDQ promotes | 河南师范大学 | 2018-01-26 | — | — | CN | claimed |
| CN-113185350-A | Weeding type bio-organic fertilizer, preparation method and application | 中科韶华(四川)牧业研究院有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-107629033-A | A kind of synthetic method of [60] fullerene benzothiophene derivative that DDQ promotes | 河南师范大学 | 2018-01-26 | — | — | CN | disclosed |
| CN-107629033-A | A kind of synthetic method of [60] fullerene benzothiophene derivative that DDQ promotes | 河南师范大学 | 2018-01-26 | — | — | CN | disclosed |
| US-6844358-B2 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040102480-A1 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2004-05-27 | — | — | US | disclosed |
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0819125-B1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
| US-4117128-A | SULFONYL BENZOFURANS AND BENZOTHIOPHENES HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | CYP2A6 213/4885ASIC3 1556/4885LOXL2 3857/4885 |
| US-20040102480-A1 | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, GCKR | CYP2A6 206/4885ASIC3 961/4885LOXL2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.